Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis

Figure 2

5-year overall survival in months for paclitaxel and dose-dense docetaxel as adjuvant chemotherapy for node positive breast cancer patients.